Accord BioPharma Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02
- Wednesday, April 5, 2023, 7:17
- Business
- Add a comment
The biosimilar for Herceptin seeks to treat several forms of HER2 cancer DURHAM, N.C., April 5, 2023 /PRNewswire/ — Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today…
About the Author
adminasapcorp has written 39744 stories on this site.